Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
redxpharma.com

See what CB Insights has to offer

Founded Year

2010

Stage

PIPE | IPO

Total Raised

$13.2M

Market Cap

0.19B

About Redx Pharma

The Redx Pharma group is focused on early-stage drug discovery and development programs at sites in Liverpool (Redx Oncology) and at Alderley Park, Cheshire (Redx Anti-infectives). Fulfilling the needs of large and mid-sized pharma companies for new pipeline compounds, Redx provides translational research capacity and expertise with a focus in areas such as cancer stem cells, tumour immunology and anti-microbial resistance. Redx completed its first major collaboration agreement with the Royal Liverpool and Broadgreen University Hospitals Trust in November 2013 to work together on new drugs to combat the growing threat of antibiotic resistance.

Redx Pharma Headquarter Location

Duncan Building, Royal Liverpool Univ. Hospital Daulby Street

Liverpool, England, L69 3GA,

United Kingdom

0151 706 4747

Latest Redx Pharma News

Proactive news headlines: CMC Markets, Redx Pharma, Mkango Resources...

Nov 15, 2021

Proactive news headlines: CMC Markets, Redx Pharma, Mkango Resources... A glance at some of the day's highlights from the Proactive Investors newswire CMC Markets PLC (LSE:CMCX) said that it may split off its contracts-for-difference (CFD) operations, labelled as the ‘leveraged’ business, from its growing investment platform and business-to-business operations. Redx Pharma PLC (AIM:REDX) said it had dosed the first cancer patient taking part in a phase II efficacy trial of its highly targeted cancer drug, RXC004. Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) said it entered into a collaboration agreement with Collins Aerospace, the world's largest Tier 1 avionics company, to deliver eye-tracking technology to the aviation industry. VietNam Holding Ltd (LSE:VNH) said it will engage closely with its portfolio companies in the south-east Asian country with regard to climate change after Prime Minister Pham Minh Chinh joined the pledge to phase out coal and commit to achieving net-zero carbon emissions by 2050. Open Orphan PLC (AIM:ORPH, OTC:OPORF) said its Venn Life Sciences arm has renewed a £1.5mln, two-year contract with an unnamed major pharmaceutical client. SkinBioTherapeutics PLC (AIM:SBTX) said it was able to bring in new institutional investors following the sale of shares by its cornerstone investor. OptiBiotix Health PLC (AIM:OPTI) has agreed a one-year lock-in after selling 3.64mln SkinBioTherapeutics shares at 55p each. This takes Opti’s holding down to 20.7% from 23.1% before the disposal. Destiny Pharma PLC (AIM:DEST) announced Peter Morgan has decided to step down as a non-executive from 31 March 2022. Nick Rodgers, chief executive, added: "On behalf of Destiny Pharma, I would like to thank Peter for his considerable contribution to the company throughout its development as a private company and the transition onto the AIM market.”  Sirius Real Estate Limited has completed the acquisition of Helix Investments Limited, the holding company of the UK-based BizSpace network, for a cash consideration of approximately £245mln. Zaim Credit Systems PLC (LSE:ZAIM) said it traded profitably in the third quarter of 2021, its fifth consecutive quarter of profitable growth, with most loans now issued via its online channel. Ariana Resources PLC (AIM:AAU) announced the start of drilling programmes at the Salinbas and Tavsan gold projects in Turkey, following a number of delays relating to COVID-19. Condor Gold PLC (AIM:CNR, TSX:COG, OTC:CNDGF) booked a loss of £591,000 during the quarter to end September 2021. During the period the company continued to de-risk the La India gold project, conducting further infill drilling, as well as some exploration drilling. Primary Health Properties PLC (LSE:PHP) has made its second acquisition in four days, buying the Bersted Green Surgery, West Sussex, for £5.34mln. Bradda Head Lithium Ltd (AIM:BHL) said it entered into a royalty agreement with Lithium Royalty Corp (LRC) over Bradda’s sedimentary lithium claims in Central Arizona. The agreement is subject to satisfactory due diligence and a site visit from LRC. ADM Energy PLC (AIM:ADME, ETR:P4JC) has raised a total of £475,000 through a share placing, to boost working capital as the company assesses a number of new investment opportunities. Mkango Resources Ltd (AIM:MKA, TSX-V:MKA, OTC:MKNGF) has launched HyProMag Limited in Germany to roll out commercialisation of hydrogen processing of magnet scrap (HPMS) technology into Germany and Europe, and to further support government initiatives to strengthen European rare earth supply chains and accelerate the green transition. Braveheart Investment Group PLC (AIM:BRH) reported soaring profits for the first half and a huge increase in the book value of its investment in PhaseFocus. Power Metal Resources PLC (AIM:POW) said it raised £1.05mln through a placing that will enable it to accelerate its  exploration activities and corporate opportunities. Panthera Resources PLC (AIM:PAT) said it issued 3.0 million shares and paid £0.5mln in cash as part of the previously announced acquisition of Metal Mining India Private Ltd (MMI), the company's joint venture partner in the Bhukia gold project. Induction Healthcare Group PLC (AIM:INHC) said it appointed Guy Mitchell as chief financial officer with immediate effect. Ergomed PLC (AIM:ERGO, ETR:2EM) announces that executive chairman Dr Miroslav Reljanović will present at the Jefferies London Healthcare Conference at 8am GMT on 16 November 2021. The presentation will be available on the news and events section of Ergomed's website. Alien Metals Ltd (AIM:UFO, OTC:ASLRF) announced that it has issued 1.4mln ordinary shares of no par value in the capital of the Company at an issue price of 0.25 pence per share ("New Ordinary Shares"). The New Ordinary Shares will rank pari passu with the existing ordinary shares in issue and application will be made to the London Stock Exchange for 1,400,000 New Ordinary Shares to be admitted to trading on AIM. Admission of the New Ordinary Shares is expected to become effective at 08.00 on or around 19 November 2021. Add related topics to MyProactive

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Redx Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Redx Pharma is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Redx Pharma Patents

Redx Pharma has filed 4 patents.

The 3 most popular patent topics include:

  • Experimental cancer drugs
  • Fluoroarenes
  • Protein kinase inhibitors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/15/2017

12/26/2017

Protein kinase inhibitors, Experimental cancer drugs, Fluoroarenes, Transcription factors, Pyridines

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/15/2017

00/00/0000

00/00/0000

00/00/0000

Grant Date

12/26/2017

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Protein kinase inhibitors, Experimental cancer drugs, Fluoroarenes, Transcription factors, Pyridines

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Redx Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Redx Pharma Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.